|

NT-112: Autologous, engineered T Cells targeting KRAS G12D Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1: 1

Top Sponsors

  • AstraZeneca1

Indications

  • KRAS G12D1
  • Pancreatic Ductal Adenocarcinoma1
  • Colorectal Carcinoma1
  • Endometrial Cancer1
  • Solid Tumor, Adult1

Duarte, California1 trial

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

Research Site

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.